

Attribution: Kim Eagle, M.D., 2012

License: Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution–Share Alike 3.0 License:**

<http://creativecommons.org/licenses/by-sa/3.0/>

We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

Attribution Key

for more information see: <http://open.umich.edu/wiki/AttributionPolicy>

Use + Share + Adapt

{ Content the copyright holder, author, or law permits you to use, share and adapt. }

-  **Public Domain – Government:** Works that are produced by the U.S. Government. (17 USC § 105)
-  **Public Domain – Expired:** Works that are no longer protected due to an expired copyright term.
-  **Public Domain – Self Dedicated:** Works that a copyright holder has dedicated to the public domain.
-  **Creative Commons – Zero Waiver**
-  **Creative Commons – Attribution License**
-  **Creative Commons – Attribution Share Alike License**
-  **Creative Commons – Attribution Noncommercial License**
-  **Creative Commons – Attribution Noncommercial Share Alike License**
-  **GNU – Free Documentation License**

Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }

-  **Public Domain – Ineligible:** Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ

{ Content Open.Michigan has used under a Fair Use determination. }

-  **Fair Use:** Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ

Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should **do your own independent analysis** to determine whether or not your use will be Fair.

CARDIOVASCULAR SEQUENCE

Coronary Artery Disease: Chronic Disease

Kim A. Eagle, M.D.

University of Michigan Health System

Fall 2012



Kim A. Eagle, MD

Director

University of Michigan
Cardiovascular Center

*Grants: NIH, Hewlett Foundation,
Mardigian Foundation, Varbedian Fund, GORE*

Consultant: NIH NHLBI

CHRONIC CORONARY ARTERY DISEASE

Key Words: Coronary plaque, angina pectoris, myocardial oxygen supply/demand, diagnostic tests for CAD

Objectives:


1. To learn how chronic CAD forms.
2. To learn how chronic CAD presents and is identified.
3. To learn how chronic CAD is treated.
4. To become familiar with risk stratification in chronic CAD.

OUTLINE

- Development of CAD
 - Clinical presentation/definitions
 - Concept of myocardial oxygen supply and demand
 - Pathophysiology of chronic ischemia syndromes
 - Diagnosis
 - Treatment strategies
 - Prognosis
-

DEVELOPMENT OF CAD

AHA CLASSIFICATION OF CAD




Initial Lesion

- From 1st decade of life
- Clinically silent


Fatty Streak

- From 1st decade of life
- Growth by lipid accumulation
- Clinically silent


AHA CLASSIFICATION



TYPE III



TYPE IV



TYPE V

Intermediate

- From 3rd decade
- Further lipid pool
- Clinically silent


Atheroma

- From 4th decade
- More lipid pool
- Clinically silent or overt

Fibroatheroma

- Lipid core
- Fibrotic layer
- Smooth muscle cells
- Clinically silent or overt

AHA CLASSIFICATION



TYPE VI

Complicated Plaque

- Surface defect
- Surface clot
- Hemorrhage in plaque
- Luminal thrombus
- From 4th decade
- Clinically overt

CLINICAL PRESENTATION / DEFINITIONS

A. DEFINITIONS

Classic Angina:

Transient discomfort or pain sensation occurring in the precordium, provoked by stress (physical or mental) and relieved by rest or nitroglycerin.

Atypical Angina:

Transient discomfort or pain that is lacking one or more of the criteria of classic angina.

Angina Equivalent:

Sensation of dyspnea, fatigue, or weakness as a manifestation of cardiac ischemia.


CLINICAL PRESENTATION / DEFINITIONS

B. CHARACTERISTICS

1. Provoked by physical or mental stress
2. Associated with ST-segment depression
3. Lasts \leq 15 minutes
4. Exercise testing usually provokes chest pain and produces ST-segment depression
5. Medical treatment with beta blockers, nitrates, or calcium channel blockers improves symptoms

Chronic CAD

Normal




*Endothelial
Cell*

- Patent lumen
- Normal endothelial function
- Platelet aggregation inhibited

Chronic CAD


Stable Angina



- Lumen narrowed by plaque
- Inappropriate vasoconstriction

Chronic CAD

Unstable Angina




Platelets

Thrombus

- Plaque rupture
- Platelet aggregation
- Thrombus formation
- Unopposed vasoconstriction

Chronic CAD

Variant Angina



- No overt plaques
- Intense vasospasm

GRADING OF ANGINA PECTORIS BY THE CANADIAN CARDIOVASCULAR SOCIETY CLASSIFICATION SYSTEM

Class I:

Ordinary physical activity does not cause angina, such as walking, climbing stairs.

Class II:

Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or climbing stairs after a meal, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Angina occurs on walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.

GRADING OF ANGINA PECTORIS BY THE CANADIAN CARDIOVASCULAR SOCIETY CLASSIFICATION SYSTEM

Class III:

Marked limitations of ordinary physical activity. Angina occurs on walking one to two blocks on the level and climbing one flight of stairs in normal conditions and at a normal pace.

Class IV:

Inability to carry on any physical activity without discomfort-anginal symptoms may be present at rest.

PATHOPHYSIOLOGY

DETERMINATES OF MYOCARDIAL OXYGEN SUPPLY AND DEMAND


CORONARY BLOOD FLOW

- Vascular tone
- Coronary perfusion pressure
- Collaterals
- Duration of diastole


MYOCARDIAL O₂ CONSUMPTION

- Wall tension
- Contractility
- Heart rate
- Preload
- Afterload

COLLATERAL FLOW



COLLATERAL FLOW



VASCULAR TONE

- External arterial compression during systole
- Intrinsic autoregulation
 - Metabolic factors
 - Reduced oxygen → vasodilation
 - Reduced ATP → adenosine → vasodilation
 - Endothelial factors
 - EDRF - NO → vasodilation
 - Prostacyclin → vasodilation
 - Endothelin-1 → vasoconstriction
 - Neural factors
 - α - adrenergic receptors → vasoconstriction
 - β - adrenergic receptors → vasodilation

CORONARY PERFUSION PRESSURE

- Approximated by diastolic blood pressure (DBP)
- Marked reductions in DBP lead to hypoperfusion... eg. hypotension, severe aortic valve regurgitation

DIASTOLE

- Flow to coronaries in systole reduced by:
 - external compression of arteries
 - local venturi effect in ascending aorta
- Heart rate ↑ compromises diastolic filling time

HEART RATE

- ↑ # of contractions requires more ATP generation.... this requires more oxygen


CONTRACTILITY

- ↑ Force of contraction requires more ATP.... increases O₂ consumption

PATHOPHYSIOLOGY OF CHRONIC ISCHEMIC SYNDROMES

- Fixed vessel narrowing
 - Endothelial cell dysfunction
 - Non-Coronary factors
-

FIXED VESSEL STENOSIS



ENDOTHELIAL CELL DYSFUNCTION

- Normal response to stress: vasodilation....increased blood flow/shear stress → sympathetic activation → EDRF - NO
 - Normal vessel: EDRF - NO outweighs α - constriction from catecholamines
 - Diseased vessel: vasoconstrictive response overcomes inadequate EDRF - NO release...."sensitized" to vasoconstrictive platelet products
-

NON-CORONARY FACTORS

Inadequate Oxygen Supply

- Anemia
- Hypoxia
- Decreased perfusion pressure...hypotension, aortic regurgitation

Increased Oxygen Demand

- Aortic stenosis
- Severe HCM
- Thyrotoxicosis

DIAGNOSIS

- History
 - Physical exam
 - Electrocardiogram
 - Exercise ECG test
 - Exercise test with imaging
 - Pharmacological stress test
 - Coronary angiography
-

HISTORY: “ANGINA”

Quality

- Tightness
- Constriction
- Not pleuritic
- Radiation - jaws, arms
- Heaviness
- Not “stabbing”
- Dull, not sharp
- Association: SOB, sweat

Duration

- Steady, lasts minutes
- More than a few seconds
- Not usually \geq 10-15 min.

Provocation

- Exertion, emotion
- Cold air
- Large meal

Relief

- Nitroglycerine - sec. to min.
- Rest

PHYSICAL EXAM

During ischemia

- ↑ BP
 - ↑ HR
 - Diaphoresis
 - Transient mitral valve regurgitation (rare)
 - Pulmonary rales (rare)
-

Not during ischemia

- Usually no abnormal findings
- Occasional associated issues:
 - aortic stenosis
 - HCM
 - aortic regurgitation

}

— systolic murmur

— diastolic murmur

ELECTROCARDIOGRAM

- Usually shows change during an episode
- Typically transient ST-segment depression or T-wave flattening/inversion
- Rarely transient ST-segment elevation

Normal



Subendocardial ischemia



ST depression
(horizontal)



ST depression
(downsloping)



T wave
inversion

Transmural
ischemia



ST elevation

EXERCISE ECG STRESS TEST

Treadmill or bicycle exercise

Constant monitoring of:

12 lead ECG

heart rate

BP (periodically)

Graded increase in exercise until:

angina occurs with ECG

changes... or

marked ischemia on ECG... or

target heart rate is reached... or

patient can no longer continue

STRESS TEST SIGNS: “SEVERE” CAD

- SX/ECG change occurs in 1st 3-6 min. of exercise or persists > 5 min. after
 - Magnitude of ST depression $\geq 2\text{mm}$
 - Systolic BP falls during exercise
 - High grade arrhythmia - eg. Sustained ventricular tachycardia - occurs
 - Cardiopulmonary limitations preclude exercise beyond 2-3 min.
-

EXERCISE TEST WITH IMAGING

Myocardial Perfusion Scintigraphy

- Nuclear tracer injected at peak exercise → image the heart
- Myocardium perfused by narrowed artery “takes” up less tracer than that served by normal coronaries
- Compare relative myocardial uptake at rest to that with exercise...
- Exercise “cold” spots that look normal at rest... viable heart muscle served by stenotic arteries
- Exercise cold spots that are also present at rest: dead heart muscle or very severe ↓ flow

EXERCISE TEST WITH IMAGING

Echocardiographic wall motion

- Image LV wall motion at rest
- Image immediately \bar{p} maximum stress
- Ischemic myocardium shows:
 - reduced systolic wall thickening
 - reduced systolic wall motion... hypokinesia/akinesia

PHARMACOLOGIC STRESS TEST: CHOICES

Adenosine - Thallium or Sestamibi:


- Vasodilator
- Myocardial perfusion image
- Narrowed vessels have ↓ vasodilatory response c/w normal
- Before/after images → “relative” ↓ tracer uptake

Dobutamine Echocardiography

- Catecholamine stress mimics exercise
 - Image for ischemia by ECG and wall motion analysis
-

CORONARY ANGIOGRAPHY

- Direct injection of radiopaque dye into coronary arteries
- Carries higher risk c/w noninvasive testing
- Most reliable method to obtain anatomical data
- When to do:
 - to establish Dx when uncertainty exists
 - to identify advanced CAD for potential revascularization Ė PCI or CABG



PD-INEL

TREATMENT STRATEGIES

- Prevent progression of atherosclerosis
 - Prevent conversion of stable to unstable lesions
 - Relieve symptoms to improve quality of life
 - Prolong life
-

PREVENT PROGRESSION OF ATHEROSCLEROSIS

- Identify / treat hyperlipidemia
 - Identify / treat hypertension
 - Identify / treat diabetes mellitus
 - Identify / treat smoking
 - Counteract obesity, sedentary lifestyle, depression, and other habits (e.g. cocaine)
-

PREVENT DESTABILIZATION OF PLAQUES

- Reduce shear stress
 - β -blocker
 - regular exercise
- Reduce thrombogenicity of blood
 - aspirin, clopidogrel
- Reduce vasoreactivity of vessels
 - β -blocker, nitrate, calcium blockers
 - no smoking
 - control lipids (statins)

RELIEVE SYMPTOMS OF ANGINA

Drug Class	Mechanism	Side Effects
β -blockers	\downarrow O ₂ demand - \downarrow Contractility \uparrow O ₂ Delivery - Slow HR	Fatigue/Depression Excess \downarrow HR Bronchospasm Impotence
Long acting nitrates	\downarrow O ₂ Demand - \downarrow Preload \uparrow O ₂ Supply - \uparrow Coronary Perfusion - \downarrow Constriction	Headache Hypotension Reflex \uparrow HR
Ca ⁺⁺ blockers	\downarrow Preload \downarrow Wall stress \downarrow HR (D,V) \uparrow Perfusion/ \downarrow Constriction	Headache Flushing Edema
Ranolazine	\downarrow Late phase Inward sodium	Dizziness, headache constipation, nausea

ANTIANGINAL THERAPY

A. NITRATES

MEDICATION	DOSAGE	ACTION	DURATION
Sublingual NTG	0.3-0.6 mg	<5 min	<30 min
Aerosol NTG	0.4 mg	<5 mg	<30 min
NTG ointment (2%)	0.5-2.0 in	<60 min	6 h
Transdermal NTG	5-15 mg	30-60 min	8-14 h
Oral isosorbide	5-30 mg	15-30 min	3-6 h
Oral isosorbide (SR)	40 mg	30-60 min	6-10 h
Oral tetranitrate	10 mg	30 min	6-12 h

ANTIANGINAL THERAPY

B. CALCIUM CHANNEL BLOCKERS

MEDICATION	DOSAGE	ONSET	PEAK	ELIMINATION	LA FORM
Diltiazem	30-90 mg tid-qid	15 min	30 min	Renal/Hepatic	Yes
Nifedipine	10-30 mg tid-qid	<20 min	1-2 h	Hepatic	Yes
Verapamil	80-120 mg tid-qid	2 h	3-4 h	Hepatic	Yes
Amlodipine	2.5-10 mg qd-bid	<3 h	7-8 h	Hepatic	No
Isradipine	2.5-5.0 mg qd-bid	2 h	6-8 h	Hepatic	No
Nicardipine	20-30 mg tid	<20 min	1 h	Hepatic	No
Felodipine	2.5-10 mg qd	2 h	2.5-5 h	Hepatic	No

ANTIANGINAL THERAPY


C. BETA BLOCKERS

MEDICATION	DOSAGE	LIPOPHILICITY	ISA	ELIMINATION	LA FORM
Atenolol	25-100 mg qd	Low	No	Renal	No
Metaprolol	25-100 mg bid	Mod	No	Hepatic	Yes
Propanonol	10-40 mg qid	High	No	Hepatic	Yes
Pindolol	5-10 mg bid	Mod	Yes	Renal	No
Labetalol	100-200 mg bid	Low	No	Hepatic	No
Acebutolol	200-400 mg bid-tid	Low	No	Hepatic	Yes
Timolol	10-30 mg bid	Mod	No	Renal/Hepatic	No

PERCUTANEOUS CORONARY INTERVENTION


- Catheter based opening of fixed artery obstruction - main use is angina not / controlled with medical Rx.
 - Multiple types of devices
 - Balloon
 - Stent
 - Rotoblator
 - Laser
 - Cutting catheter
 - Drug Eluting Stent
 - Relieves angina caused by stenoses of > 50-60%... esp. when more severe
 - Does not prevent acute MI in stable angina... issue is restenosis in 15-40% of pts.
-

Chronic CAD




Stent in its original collapsed state, is advanced into the coronary stenosis on a balloon catheter.

Chronic CAD



Balloon inflation to expand stent

Chronic CAD



The balloon is deflated and the catheter is removed from the body, leaving the stent permanently in place.

CORONARY ARTERY BYPASS SURGERY

- Surgically bypass arteries with advanced fixed obstruction
 - Involves up front risk of death, stroke, sternal infection, post-op debility
 - Relieves angina reliably
 - Prolongs life in select anatomic subsets
 - Disease can return in bypass grafts... arterial grafts preferred... left internal mammary artery to LAD
-

Chronic CAD

Relative Advantages of Coronary Revascularization Procedures

Percutaneous Coronary Interventions (PCI)

- Less invasive than CABG
- Shorter hospital stay and easier recuperation than CABG
- Superior to pharmacological therapy for relief of angina

Coronary Artery Bypass Graft Surgery (CABG)

- More effective for long-term relief of angina than PCI or pharmacologic therapy
- Most complete survival in patients with:
 - > 50% left main stenosis
 - 3-vessel CAD, especially if LV contractile function is impaired
 - 2-vessel disease with tight (>75%) LAD stenosis, especially if LV contractile function is impaired
 - Diabetes and multivessel disease


CAD, coronary artery disease; LV, left ventricle; LAD, left anterior descending coronary artery; MI, myocardial infarction.

Lilly L, et al. *Pathophysiology of Heart Disease* 2007;166.

CHRONIC STABLE ANGINA: THERAPEUTIC BENEFITS

- Improves symptoms:
 - β -blocker
 - Nitrates
- Prevents acute ischemic syndromes:
 - ASA
 - β -blocker
- Prolongs life
 - CABG in:
 - Lipid lowering drugs





PROGNOSIS

MAJOR PREDICTORS:

- Advanced age
- LV dysfunction
- Extent of CAD

1 vessel

Annual mortality

< 4%

2 vessel

7 - 10%

3 vessel

10 - 12%

Left main

15 - 25%

CORONARY ARTERY DISEASE PROGNOSTIC INDEX

<u>EXTENT OF CAD</u>	<u>5 - YEAR SURVIVAL RATE (%)</u>
1 - vessel disease, 75%	93
>1 - vessel disease, 50% to 74%	93
1 - vessel disease, \geq 95%	91
2 - vessel disease	88
2 - vessel disease, both \geq 95%	86
1 - vessel disease, \geq 95% proximal LAD	83
2 - vessel disease, \geq 95% LAD	83
2 - vessel disease, \geq 95% LAD	79
3 - vessel disease	79
3 - vessel disease, \geq 95% in at least 1	73
3 - vessel disease, 75% proximal LAD	67
3 - vessel disease, \geq 95% proximal LAD	59

CHRONIC STABLE ANGINA

- Development
 - Clinical definitions
 - Myocardial oxygen supply and demand
 - Pathophysiology
 - Diagnosis
 - Treatment strategies
 - Prognosis
-